We are live on ! Find out more
ATRS

Antares Pharma, Inc.
ATRS

Delisted

ATRS was delisted on the 23rd of May, 2022.

Back to rankings

0 hedge funds and large institutions have $0 invested in Antares Pharma, Inc. in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $12K → $0 (-$12K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
–
Holders Change
-1
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

1
IA
IFP Advisors
Florida
-$12K
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
1
IFP Advisors
Florida
– -$12K -4,369 Closed

ATRS Hedge Fund Activity: Q4 2022 in Review

0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q4 2022, worth a combined $0 — down 100% from $12K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of ATRS and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was IFP Advisors, exiting entirely with an estimated $12K sold.

  • 0 institutional investors held Antares Pharma, Inc. (ATRS) as of Q4 2022, down from 1 in Q3 2022.
  • Funds reported $0 of Antares Pharma, Inc. stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Antares Pharma, Inc. positions in Q4 2022 and 1 closed out, a net change of -1 holder.
  • The largest Antares Pharma, Inc. seller in Q4 2022 was IFP Advisors, an estimated $12K sold.

Based on aggregated 13F filings for Q4 2022.